{"id":751066,"date":"2023-04-25T17:02:49","date_gmt":"2023-04-25T21:02:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/"},"modified":"2023-04-25T17:02:49","modified_gmt":"2023-04-25T21:02:49","slug":"gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/","title":{"rendered":"Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO and SUZHOU, China and SHANGHAI, China, April  25, 2023  (GLOBE NEWSWIRE) &#8212; Gracell Biotechnologies Inc. (NASDAQ: GRCL) (\u201cGracell\u201d), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2022 with the U.S. Securities and Exchange Commission (\u201cSEC\u201d) on April 25, 2023.<\/p>\n<p align=\"left\">The annual report is available on the company\u2019s investor relations website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NGXclYxBYg9SrL14mPjr1pXYuc7kc7hLb7gTcrQ2V3HaAAzIUsxWlNgeg0lG4xvvEycHTGABdakadDPS7YuhPQ==\" rel=\"nofollow noopener\" target=\"_blank\">ir.gracellbio.com<\/a> and on the SEC\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1sMnPZPk1IyPVI16syk0inQ4oVUT7svYUzOZ3KdMcoAJ3ygu0Bu2gex3ACOSRTue8vgnAczEQI-hOLAZuw-01Q==\" rel=\"nofollow noopener\" target=\"_blank\">www.sec.gov<\/a>. The company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request. Requests should be directed to Investor Relations, Gracell Biotechnologies, 41th Floor, Building A, No. 188 Hongbaoshi Road, Changning District, Shanghai, 201103, People\u2019s Republic of China.<\/p>\n<p align=\"left\">\n        <strong>About Gracell<\/strong><br \/>\n        <br \/>Gracell Biotechnologies Inc.\u00a0(&#8220;Gracell&#8221;) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CAR\u2122 technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-6s46hpqNH94XIDhHy6c-FZq6Pt7cB5R5lQw_jGBNdFf2F2D4AqQP30D4TrNEkr6H5-twPXZjfnBf2XsFj9WUwAU1X47fVi08HZSY6vfXTU=\" rel=\"nofollow noopener\" target=\"_blank\">www.gracellbio.com<\/a>.\u00a0Follow @GracellBio on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W92uuEabFv9TVme_cISBgnyOcO2fhalNPeTbrkjwoiYzpKj7FARPR1sYLDgcqxmV_GcZywXBPlb_F-ZZRLkKITg4PPrO24idDwYiUI3N53I=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"left\">\n        <strong>Cautionary Noted Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#8220;forward-looking statements&#8221; within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing date of the offering. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the section entitled &#8220;Risk Factors&#8221; in Gracell&#8217;s most recent annual report on Form 20-F as well as discussions of potential risks, uncertainties, and other important factors in Gracell&#8217;s subsequent filings with the\u00a0Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Gracell specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Readers should not rely upon the information on this page as current or accurate after its publication date.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTQ1MyM1NTU2OTU3IzIyMDQyODY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MzE0NWI3YjctZWI0Mi00OWYwLWExNDAtYTMwYjYyOWVmMDcyLTEyMTU4Mzk=\/tiny\/Gracell-Biotechnologies-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Media contacts\r\n\r\nMarvin Tang\r\nmarvin.tang@gracellbio.com\r\n\r\nKyle Evans\r\nkyle.evans@westwicke.com\r\n\r\nInvestor contacts\r\n\r\nGracie Tong\r\ngracie.tong@gracellbio.com\r\n\r\nStephanie Carrington\r\nstephanie.carrington@westwicke.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO and SUZHOU, China and SHANGHAI, China, April 25, 2023 (GLOBE NEWSWIRE) &#8212; Gracell Biotechnologies Inc. (NASDAQ: GRCL) (\u201cGracell\u201d), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2022 with the U.S. Securities and Exchange Commission (\u201cSEC\u201d) on April 25, 2023. The annual report is available on the company\u2019s investor relations website at ir.gracellbio.com and on the SEC\u2019s website at www.sec.gov. The company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request. Requests should be directed to Investor &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751066","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO and SUZHOU, China and SHANGHAI, China, April 25, 2023 (GLOBE NEWSWIRE) &#8212; Gracell Biotechnologies Inc. (NASDAQ: GRCL) (\u201cGracell\u201d), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2022 with the U.S. Securities and Exchange Commission (\u201cSEC\u201d) on April 25, 2023. The annual report is available on the company\u2019s investor relations website at ir.gracellbio.com and on the SEC\u2019s website at www.sec.gov. The company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request. Requests should be directed to Investor &hellip; Continue reading &quot;Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-25T21:02:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTQ1MyM1NTU2OTU3IzIyMDQyODY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022\",\"datePublished\":\"2023-04-25T21:02:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\\\/\"},\"wordCount\":462,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTQ1MyM1NTU2OTU3IzIyMDQyODY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\\\/\",\"name\":\"Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTQ1MyM1NTU2OTU3IzIyMDQyODY=\",\"datePublished\":\"2023-04-25T21:02:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTQ1MyM1NTU2OTU3IzIyMDQyODY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTQ1MyM1NTU2OTU3IzIyMDQyODY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/","og_locale":"en_US","og_type":"article","og_title":"Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022 - Market Newsdesk","og_description":"SAN DIEGO and SUZHOU, China and SHANGHAI, China, April 25, 2023 (GLOBE NEWSWIRE) &#8212; Gracell Biotechnologies Inc. (NASDAQ: GRCL) (\u201cGracell\u201d), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2022 with the U.S. Securities and Exchange Commission (\u201cSEC\u201d) on April 25, 2023. The annual report is available on the company\u2019s investor relations website at ir.gracellbio.com and on the SEC\u2019s website at www.sec.gov. The company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request. Requests should be directed to Investor &hellip; Continue reading \"Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-25T21:02:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTQ1MyM1NTU2OTU3IzIyMDQyODY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022","datePublished":"2023-04-25T21:02:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/"},"wordCount":462,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTQ1MyM1NTU2OTU3IzIyMDQyODY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/","name":"Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTQ1MyM1NTU2OTU3IzIyMDQyODY=","datePublished":"2023-04-25T21:02:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTQ1MyM1NTU2OTU3IzIyMDQyODY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTQ1MyM1NTU2OTU3IzIyMDQyODY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-announces-filing-of-its-annual-report-on-form-20-f-for-fiscal-year-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751066"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751066\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}